Bioneer

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Bioneer - overview

Established

1992

Location

Oakland, CA, US

Primary Industry

Biotechnology

About

Bioneer is a biotechnology company focused on delivering advanced solutions and products for research, healthcare, and agriculture through innovative molecular biology tools for genetic analysis and manipulation. Founded in 1992, Bioneer operates in Oakland, US, providing advanced biotechnology solutions. The company has maintained a consistent focus on developing sophisticated tools for molecular biology, without significant pivots in its business strategy. The CEO, Han-Oh Park, is among the founders, but there are no known details about previous ventures.


Currently, Bioneer has no identified parent or subsidiary companies. Bioneer specializes in advanced biotechnology products and services that cater to various sectors, including research, healthcare, and agriculture. The company’s core offerings revolve around molecular biology tools, particularly those that facilitate genetic analysis and manipulation. These products are designed to serve a diverse clientele, including academic institutions, pharmaceutical companies, and agricultural developers, focusing on enhancing research efficiency and precision in genetic studies.


Bioneer's product lineup addresses critical end-use cases such as diagnostics, therapeutic development, and agricultural improvements, enabling clients to achieve breakthroughs in their respective fields. The company has strategically positioned its products in key geographical markets, including North America, Europe, and parts of Asia, ensuring a broad reach and impact across the biotechnology landscape. Bioneer's revenue model is structured around a combination of direct-to-consumer sales and B2B partnerships, facilitating transactions with both institutional and retail customers. The company generates revenue through the sale of proprietary biotechnology products, along with potential service contracts for specialized support and training.


Clients may engage in multi-year agreements, ensuring a steady stream of income through subscriptions for ongoing access to technical resources and product updates. Specific pricing plans for flagship products are tailored to meet the varying needs of clients, reflecting the specialized nature of Bioneer's offerings. This transactional framework enables Bioneer to maintain robust relationships with its user base while continuously expanding its market presence.


Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development

Website

http://www.bioneer.com

Total Amount Raised

Subscriber access only

Bioneer - employee data

Blurred Background

Want to see Employee Count?

Request a demo for full access to this profile.

GoingPro

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.